- Details
- Description
Packaging Size:
30t/bottle
Strength:
100mg
Composition:
Vandetanib
Treatment:
Medullary Thyroid Cancer
Form:
Tablet
Brand:
LuciVande 100
Quantity Unit:
100mg*30t/Box
Manufacturer:
Lucius Pharmaceuticals (Lao) Co.,Ltd
About Vandetanib
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Medullary Thyroid Cancer
Indicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
300 mg PO qDay with or without food
Continued until disease progression or unacceptable toxicity occurs
Dosage Modifications
Dose Reduction
- Grade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary
-
Interrupt therapy
- Corrected QT interval, Fridericia (QTcB) interval >500 msec: Resume at reduce dose once QTcF ≤450 msec
- Grade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade <1
- Recurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade <1, if continued treatment is warranted
Renal impairment
- CrCl ≥50 mL/min: No dosage adjustment necessary
- Moderate (CrCl 30 to <50 mL/min): Reduce starting dose to 200 mg PO qDay
- Severe (CrCl <30 mL/min): Not recommended
- End-stage renal disease requiring dialysis: Not studied
Hepatic impairment
- Mild (Child Pugh A): Dose adjustment not described in manufacturer's label
- Moderate-to-severe (Child-Pugh B or C): Not recommended
